Friday, September 11, 2015

SYGNIS presents your innovative True Prime Technology on Single Cell … –

SYGNIS presents your innovative True Prime technology
 the Single Cell Genomics Conference 2015

DGAP-News: SYGNIS AG / Key word (s): Conference SYGNIS presents
 Your innovative True Prime Technology on Single Cell
 Genomics Conference 2015

09.10.2015 / 13:44

Press Release

SYGNIS presents your innovative True Prime Technology on the
 Single Cell Genomics Conference 2015

Madrid, Spain and Heidelberg, August 10, 2015 – SYGNIS AG
 (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) announced today
 known to their proprietary True Prime Technology
 the Single Cell Genomics Conference in 2015, in front of experts from
 Universities, companies, associations and government representatives
 will present. This year’s conference is organized by
 Dutch Hubrecht aligned Institute and will take place from 16th
 to 18 September in Utrecht instead.

SYGNIS ‘product portfolio to amplify True Prime
 complete genomes from very small amounts of biological samples to
 down to single cells, based on a revolutionary new
 Multiple Displacement Amplifiations (MDA) technology for the
 Multiplication of various DNA and RNA forms for
 wide range of applications. Using the
 proprietary DNA primase TthPrimPol requires the
 True, in contrast to current Prime Technology
 Standard technologies no synthetic “primer” (short
 DNA molecules, oligonucleotides) to start the reaction.

The properties of the True Prime technology make this
 Product very attractive for a wide range of applications and
 Analyzes, particularly in life science fields such as of the
 Genome analysis of single cells, where researchers biological information
 must win from the smallest samples.

Armin Schneider, senior vice president of research at SYGNIS, is
 a poster entitled True Prime, a superior technology for
 single cell whole genome amplification based on TthPrimPol,
 imagine. The poster presentations will be on September 16 from
 18:25 until 21:00 clock and on 17 September from 17:10 until 19:30 clock
 take place.

The single-cell genomics is rapidly developing into a
 important technology for many areas of biological research.
 By the versatile application possibilities (sequencing
 Single cell genomes, analyzing Einzelzelltranskriptomen,
 Different approaches in the field of epigenetic profiling
 Single cells), the researchers, the genetic and functional
 Properties of individual cells under native conditions
 characterize, whereby numerous experimental and
 open clinical opportunities.

For more information on the Single Cell Genomics Conference 2015
 can be found at:

Über True Prime

True Prime is the brand name of a revolutionary, new
 Multiple Displacement Amplification and one of the
 Key products in SYGNIS ‘portfolio. True Prime is based on
 the combination of the company’s DNA primase “TthPrimPol” with
 a highly processive and accurate Phi29 polymerase for
 uniform amplification of complete genomes for
 wide range of applications such as Next Generation Sequencing (NGS)
 and the analysis of single cells. The extraordinary ability of
 Phi29 polymerase for the separation of DNA duplexes allowed the
 direct formation of new primer by TthPrimPol on the straight
 exposed strands. These primers serve as attachment points for
 Phi29 polymerase, which then directly starts with the amplification, which
 an exponential DNA amplification under isothermal conditions
 leads without the previously necessary use of synthetic
 . Primers

For further information, please contact:

 Pilar de la Huerta Raimund Gabriel
 CEO / CFO Managing Partner
 Tel .: +34 91 192 36 50 210 228 89 30 Tel .: +49
 Email: Email:


SYGNIS, with headquarters in Germany and Spain, specializes in
 developing and commercializing innovative products for the
 DNA amplification and sequencing. Based on its
 proprietary technologies, SYGNIS has a commercial
 Developed product portfolio in the key challenges
 the rapidly growing fields of molecular biology and the Next
 Generation Sequencing addressed. The main products of the company
 are on the one hand for the amplification and sequencing
 complete genomes developed True Prime product line and
 SensiPhi (R) attached to an industry-leading partners
 was licensed. Furthermore includes the product portfolio
 SunScript reverse transcriptase product family for translation
 genetic information from RNA to DNA a. SYGNIS AG is listed in Prime
 Standard of Deutsche Börse (Ticker: LIO1; ISIN: DE000A1RFM03)

### Certain statements contained in this press release in
 where there are neither reported financial results nor
 other historical information are, are forward-looking nature. It
 Such statements are mainly predictions of future results, trends,
 Plans or objectives. Such statements are not backed up as absolute
 to consider, as they naturally known and unknown risks
 and are subject to uncertainties and influenced by other factors
 can be, in consequence of which the actual results and the
 Plans and goals of SYGNIS materially from those expressed or
 can differ implied forward-looking statements. SYGNIS
 undertakes no obligation to update these statements publicly
 to revise or, whether to reflect new information, future
 Events or circumstances or otherwise. ###

09.10.2015 Dissemination of a Corporate News / financial news
 transmitted by DGAP – a service of EQS Group AG. For the
 Content of this announcement is the issuer / publisher responsible.

DGAP’s Distribution Services include Regulatory Announcements,
 Financial / Corporate News and Press Releases.
 Media archive at and

Language: German
 Company: SYGNIS AG
                 Waldenhofer Str. 104
                 69123 Heidelberg
 Phone: 03222 1091 975
 Fax: 03222 1096 030
 Exchanges: Regulated Market in Frankfurt (Prime Standard);
                 Freiverkehr in Berlin, Dusseldorf, Hamburg, Munich,

End of News DGAP News-Service

393 705 09/10/2015


AXC0113 2015-09-10 / 13: 44


No comments:

Post a Comment